Trial Profile
Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs P-BCMA-101 (Primary) ; Rimiducid
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Poseida Therapeutics
- 30 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 26 Aug 2019 Planned number of patients changed from 40 to 100.
- 20 Nov 2018 New trial record